Serlopitant Tablet + Placebo Oral Tablet
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermolysis Bullosa
Conditions
Epidermolysis Bullosa
Trial Timeline
Apr 18, 2019 → Jun 24, 2022
NCT ID
NCT03836001About Serlopitant Tablet + Placebo Oral Tablet
Serlopitant Tablet + Placebo Oral Tablet is a phase 2 stage product being developed by Vyne Therapeutics for Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT03836001. Target conditions include Epidermolysis Bullosa.
What happened to similar drugs?
0 of 7 similar drugs in Epidermolysis Bullosa were approved
Approved (0) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03836001 | Phase 2 | Completed |
Competing Products
13 competing products in Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod | Argenx | Phase 1/2 | 36 |
| KB803 + Placebo | Krystal Biotech | Phase 3 | 44 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 29 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 37 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 37 |
| SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) | Amicus Therapeutics | Phase 2 | 32 |
| SD-101-6.0 cream + Placebo (SD-101-0.0) cream | Amicus Therapeutics | Phase 3 | 37 |
| SD-101-6.0 cream | Amicus Therapeutics | Phase 3 | 29 |
| SD-101 dermal cream (6%) | Amicus Therapeutics | Phase 2 | 24 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 22 |
| EB-101 | Abeona Therapeutics | Phase 3 | 30 |
| EB-101 Surgical application of RDEB wounds | Abeona Therapeutics | Phase 3 | 34 |
| VPD-737 | Vyne Therapeutics | Phase 2 | 25 |